Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has issued an announcement.
Artrya Limited announced the issuance of 326,752 ordinary shares following the exercise and conversion of vested employee incentive options. Additionally, 3,319,703 performance rights lapsed and were canceled. This move reflects Artrya’s ongoing efforts to manage its equity and incentivize employees, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.21 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. Artrya is actively engaged in regulatory and commercial activities across key international markets.
Average Trading Volume: 204,645
Technical Sentiment Signal: Buy
For a thorough assessment of AYA stock, go to TipRanks’ Stock Analysis page.